Clinical Trials
108 trialsNCT00869232 2026-05-22
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Active not recruiting
NCT07085728 2026-05-15
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05497804 2026-05-13
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Mayo Clinic
Phase 2 Active not recruiting
NCT06169215 2026-05-13
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06948084 2026-05-13
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT04508790 2026-05-04
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
Phase 2 Recruiting
NCT05972135 2026-04-22
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT01816971 2026-04-21
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
Phase 2 Completed
NCT03763162 2026-04-15
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04835129 2026-03-27
IMPEDE
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT05272826 2026-03-18
BOREALIS
Canadian Myeloma Research Group
Phase 2 Recruiting
NCT05690984 2026-03-16
EMAT
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT04883242 2026-03-13
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Active not recruiting
NCT04151667 2026-03-11
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT01572480 2026-03-10
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05530421 2026-02-23
SELVEDge
University of Miami
Phase 2 Recruiting
NCT04661137 2026-02-10
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Hackensack Meridian Health
Phase 2 Suspended
NCT04414475 2026-02-02
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Karyopharm Therapeutics Inc
Phase 2 Recruiting
NCT04430894 2026-01-29
KRDI in Transplant-Eligible MM
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04240054 2026-01-28
VICD
Medical College of Wisconsin
Phase 2 Recruiting
NCT02718833 2026-01-22
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT02441686 2026-01-13
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06627751 2026-01-12
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT04009109 2025-12-18
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
NCT02253316 2025-11-10
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT03590652 2025-10-21
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
Phase 2 Terminated
NCT02412228 2025-10-15
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
Brown University
Phase 2 Completed
NCT03004287 2025-09-10
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
University of Arkansas
Phase 2 Active not recruiting
NCT01559935 2025-09-08
CarBiRD
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT01415882 2025-09-05
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Mayo Clinic
Phase 2 Completed
NCT04191616 2025-09-04
SELECT
Amgen
Phase 2 Completed
NCT05208307 2025-09-02
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Emory University
Phase 2 Recruiting
NCT05288062 2025-08-20
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
Phase 2 Terminated
NCT04635189 2025-08-08
Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
University of Rochester
Phase 2 Active not recruiting
NCT04775550 2025-07-02
PRISM
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02765854 2025-06-26
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Emory University
Phase 2 Completed
NCT03713294 2025-06-24
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT03012880 2025-06-04
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT03756896 2025-04-30
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
Emory University
Phase 2 Active not recruiting
NCT06140966 2025-04-16
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT03457142 2025-03-04
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
Roswell Park Cancer Institute
Phase 2 Terminated
NCT04700176 2025-02-25
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
NCT01903811 2024-12-20
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
SWOG Cancer Research Network
Phase 2 Completed
NCT02375555 2024-10-01
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04756401 2024-09-26
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT03000634 2024-09-05
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
University of Arkansas
Phase 2 Withdrawn
NCT05050305 2024-07-16
Marizomib Central Nervous System (CNS)
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT02654990 2024-07-12
PANORAMA_3
pharmaand GmbH
Phase 2 Completed
NCT05820763 2024-07-10
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
Washington University School of Medicine
Phase 2 Withdrawn
NCT04352205 2024-07-01
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
Phase 2 Terminated